Journal article
Risk of Ovarian Cancer and the NF-kappa B Pathway: Genetic Association with IL1A and TNFSF10
Bridget Charbonneau, Matthew S Block, William R Bamlet, Robert A Vierkant, Kimberly R Kalli, Zachary Fogarty, David N Rider, Thomas A Sellers, Shelley S Tworoger, Elizabeth Poole, Harvey A Risch, Helga B Salvesen, Lambertus A Kiemeney, Laura Baglietto, Graham G Giles, Gianluca Severi, Britton Trabert, Nicolas Wentzensen, Georgia Chenevix-Trench, Alice S Whittemore Show all
CANCER RESEARCH | AMER ASSOC CANCER RESEARCH | Published : 2014
Abstract
A missense single-nucleotide polymorphism (SNP) in the immune modulatory gene IL1A has been associated with ovarian cancer risk (rs17561). Although the exact mechanism through which this SNP alters risk of ovarian cancer is not clearly understood, rs17561 has also been associated with risk of endometriosis, an epidemiologic risk factor for ovarian cancer. Interleukin-1α (IL1A) is both regulated by and able to activate NF-κB, a transcription factor family that induces transcription of many proinflammatory genes and may be an important mediator in carcinogenesis. We therefore tagged SNPs in more than 200 genes in the NF-κB pathway for a total of 2,282 SNPs (including rs17561) for genotype anal..
View full abstractRelated Projects (4)
Grants
Awarded by European Community
Awarded by Cancer Research UK
Awarded by NIH
Awarded by Post-Cancer GWAS initiative
Awarded by Department of Defence
Awarded by Kathryn Sladek Smith
Awarded by US National Cancer Institute GAME-ON Post-GWAS Initiative
Awarded by Wellcome Trust
Awarded by American Cancer Society Early Detection Professorship
Awarded by Canadian Institutes of Health Research New Investigator award
Awarded by American Cancer Society
Awarded by California Cancer Research Program
Awarded by Canadian Institutes for Health Research
Awarded by Celma Mastry Ovarian Cancer Foundation the Danish Cancer Society
Awarded by Imperial Experimental Cancer Research Centre
Awarded by Polish Ministry of Science and Higher Education
Awarded by U.S. Army Medical Research and Materiel Command
Awarded by U.S. National Cancer Institute
Awarded by NIH/National Center for Research Resources/General Clinical Research Center
Awarded by U.S. Army Medical Research and Material Command
Awarded by National Health and Medical Research Council of Australia
Awarded by German Federal Ministry of Education and Research of Germany Programme of Clinical Biomedical Research
Awarded by state of Baden-Wurttembergthrough Medical Faculty of the University of Ulm
Awarded by Lon V. Smith Foundation
Awarded by DIVISION OF CANCER CONTROL &POPULATION SCIENCE
Awarded by DIVISION OF CANCER PREVENTION AND CONTROL
Awarded by NATIONAL CANCER INSTITUTE
Awarded by NATIONAL CENTER FOR RESEARCH RESOURCES
Awarded by The Francis Crick Institute
Funding Acknowledgements
Funding for the iCOGS infrastructure came from: the European Community's Seventh Framework Programme under grant agreement no 223175 (HEALTH-F2-2009-223175; COGS), Cancer Research UK (C1287/A10118, C1287/A 10710, C12292/A11174, C5047/A8384, C5047/A15007, C5047/A10692), the NIH (CA128978) and Post-Cancer GWAS initiative (No. 1 U19 CA 148537-the GAME-ON initiative), the Department of Defence (W81XWH-10-1-0341), the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer, Komen Foundation for the Cure, the Breast Cancer Research Foundation, and the Ovarian Cancer Research Fund.The OCAC is supported by a grant from the Ovarian Cancer Research Fund thanks to donations by the family and friends of Kathryn Sladek Smith (PPD/RPCI.07). The scientific development and funding for this project were in part supported by the US National Cancer Institute GAME-ON Post-GWAS Initiative (U19-CA148112). This study made use of the data generated by the Wellcome Trust Case Control consortium. A full list of the investigators who contributed to the generation of the data is available at http://www.wtccc.org.uk/. Funding for the project was provided by the Wellcome Trust under award 076113.B. Charbonneau is supported by R25 CA92049. G. Chenevix-Trench and P.A. Fasching are supported by the Deutsche Krebshilfe. B.Y. Karlan holds an American Cancer Society Early Detection Professorship (SIOP-06-258-01-COUN). L.E. Kelemen is supported by a Canadian Institutes of Health Research New Investigator award (MSH-87734).Funding of the constituent studies was provided by the Minnesota Ovarian Cancer Alliance; the Mayo Foundation; the Fred C. and Katherine B. Andersen Foundation; the American Cancer Society (CRTG-00-196-01-CCE); the California Cancer Research Program (00-01389V-20170, N01-CN25403, 2II0200); the Canadian Institutes for Health Research (MOP-86727); Cancer Council Victoria; Cancer Council Queensland; Cancer Council New South Wales; Cancer Council South Australia; Cancer Council Tasmania; Cancer Foundation of Western Australia; the Cancer Institute of New Jersey; Cancer Research UK (C490/A6187, C490/A10119, C490/A10124, C536/A13086, C536/A6689); the Celma Mastry Ovarian Cancer Foundation the Danish Cancer Society (94-222-52); ELAN Funds of the University of Erlangen-Nuremberg; the Eve Appeal; the Helsinki University Central Hospital Research Fund; Sigrid Juselius Foundation; Imperial Experimental Cancer Research Centre (C1312/A15589); the Ovarian Cancer Research Fund; Nationaal Kankerplan of Belgium; the L & S Milken Foundation; the Polish Ministry of Science and Higher Education (4 PO5C 028 14, 2 PO5A 068 27); the Roswell Park Cancer Institute Alliance Foundation; the U.S. Army Medical Research and Materiel Command (W81XWH-07-1-0449); the U.S. National Cancer Institute (K07-CA80668, K07-CA095666, K07-CA143047, K22-CA138563, N01-CN55424, N01-PC067010, N01-PC035137, P01-CA017054, P01-CA087696, P30-CA072720, P50-CA105009, P50-CA136393, R01-CA014089, R01-CA016056, R01-CA017054, R01-CA049449, R01-CA050385, R01-CA054419, R01-CA058598, R01-CA058860, R01-CA061107, R01-CA061132, R01-CA063682, R01-CA064277, R01-CA067262, R01-CA071766, R01-CA074850, R01-CA076016, R01-CA080742, R01-CA080978, R01-CA087538, R01-CA092044, R01-095023, R01-CA106414, R01-CA122443, R01-CA112523, R01-CA114343, R01-CA126841, R01-CA149429, R03-CA113148, R03-CA115195, R37-CA070867, R37-CA70867, U01-CA069417, U01-CA071966, and Intramural research funds); NIH/National Center for Research Resources/General Clinical Research Center grant MO1-RR000056; the U.S. Army Medical Research and Material Command (DAMD17-98-1-8659, DAMD17-01-1-0729, DAMD17-02-1-0666, DAMD17-02-1-0669); the National Health and Medical Research Council of Australia (199600, 400281, 209057, 251533, 396414, 504715); the German Federal Ministry of Education and Research of Germany Programme of Clinical Biomedical Research (01 GB 9401); the state of Baden-Wurttembergthrough Medical Faculty of the University of Ulm (P.685); the Lon V. Smith Foundation (LVS-39420); the Oak Foundation; the OHSU Foundation; the Mermaid I project; the Rudolf-Bartling Foundation; the UK National Institute for Health Research Biomedical Research Centres at the University of Cambridge, Imperial College London, University College London Hospital and the Royal Marsden Hospital; WorkSafeBC; Helse Vest, The Norwegian Cancer Society, The Research Council of Norway (HBS/NOR).